Mitch Bloom > Goodwin > Boston, United States > Lawyer Profile

Goodwin’s signature technology expertise is a big draw for start-ups, while it also leverages a dominant life sciences offering that ‘provides everything a biotech company could need’. Alongside its company-side credentials, the group maintains close links with investors and it routinely advises venture capital funds on fundraisings, investments, and exits. From Boston, Mitch Bloom steers the life science practice and specializes in advising public and private life sciences companies and investors on financings, M&A, and public offerings. The technology and emerging companies team is co-led by Boston-based duo John Egan and Kenneth Gordon, together with Silicon Valley’s Craig Schmitz , all of whom act for an array of start-ups, growth companies, and investors. Other contacts in Boston include Bill Schnoor, who, as previous head of the London office, is recommended for cross-border transactions involving the technology and life sciences sectors; Danielle Lauzon, who is recognized for her cutting-edge expertise in the life sciences field; and William Collins, who excels in matters involving the biotechnology, pharmaceuticals, and medical devices spheres. In Silicon Valley, Caine Moss focuses on supporting software, AI, internet, and financial services companies through all stages of their growth.

Goodwin’s global practice advises biotech, pharma, and healthcare companies, along with life science venture capital and investment firms. The growing practice supports clients in matters as wide-ranging as regulatory compliance, IP and M&A. The team’s representation of Prime Medicine in its $3.5bn deal with Bristol Myers Squibb evidences its excellence in research collaboration and license agreement matters. The practice is headed by Kingsley Taft, vastly experienced in commercial, financing and capital market transactions, and Mitchell Bloom, who specializes in emerging companies and life sciences investors. Both in Boston, transactional lawyer Robert Puopolo and Marishka DeToy, who focuses on capital markets and corporate matters, are key figures in the practice. In DC, Steven Tjoe focuses on product development strategies and FDA regulatory counseling. Arriving on the Boston-based team from Cooley LLP are Joshua Rottner, venture capital and growth equity funds specialist, and Michael McGrail, focused on medical devices and life sciences. Other key hires include litigation expert Michael Siekman, arriving in Boston from McDermott Will & Emery LLP, M&A specialist Amanda Gill, from Paul, Weiss, Rifkind, Wharton & Garrison LLP, and IP lawyer Carl Morales, from Fenwick & West LLP; the latter two are based in New York.